Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 662

1.

Comparative analysis of targeted novel therapies in relapsed, refractory chronic lymphocytic leukaemia.

Eyre TA, Lamanna N, Roeker LE, Ujjani CS, Hill BT, Barr PM, Lansigan E, Cheson BD, Yazdy M, Allan JN, Rhodes J, Schuster SJ, Nabhan C, Skarbnik A, Leslie L, Islam P, Whitaker K, Coombs CC, Tuncer HH, Pagel JM, Jacobs R, Winter AM, Bailey N, Sitlinger A, Schuh AH, Follows G, Fox CP, Brander DM, Shadman M, Mato AR.

Haematologica. 2020 Feb 20. pii: haematol.2019.241539. doi: 10.3324/haematol.2019.241539. [Epub ahead of print] No abstract available.

2.

Complete recovery of late onset progressive multifocal leukoencephalopathy related to treatment with chemoimmunotherapy: A case report.

Godbole MM, Barr PM.

Leuk Res. 2020 Jan 21;90:106309. doi: 10.1016/j.leukres.2020.106309. [Epub ahead of print] No abstract available.

PMID:
32004701
3.

Initial treatment of B-cell prolymphocytic leukemia with ibrutinib.

Moore J, Baran AM, Meacham PJ, Evans AG, Barr PM, Zent CS.

Am J Hematol. 2020 Jan 17. doi: 10.1002/ajh.25733. [Epub ahead of print] No abstract available.

PMID:
31951033
4.

Efficacy of lenalidomide in high-risk diffuse large B-cell lymphoma.

Rodgers TD, Baran A, Reagan PM, Casulo C, Zent C, Evans A, Burack R, Williams AM, Friedberg JW, Barr PM.

Br J Haematol. 2020 Feb;188(4):e33-e36. doi: 10.1111/bjh.16302. Epub 2019 Dec 17. No abstract available.

PMID:
31845324
5.

The Genetics of Externalizing Problems.

Barr PB, Dick DM.

Curr Top Behav Neurosci. 2019 Dec 17. doi: 10.1007/7854_2019_120. [Epub ahead of print]

PMID:
31845132
6.

Which adolescent factors predict alcohol misuse in young adulthood? A co-twin comparisons study.

Stephenson M, Barr P, Ksinan A, Aliev F, Latvala A, Viken R, Rose R, Kaprio J, Dick D, Salvatore JE.

Addiction. 2019 Nov 20. doi: 10.1111/add.14888. [Epub ahead of print]

PMID:
31746044
7.

Medical Students' Knowledge and Attitudes Toward Shared Decision Making: Results From a Multinational, Cross-Sectional Survey.

Yen RW, Barr PJ, Cochran N, Aarts JW, Légaré F, Reed M, O'Malley AJ, Scalia P, Painchaud Guérard G, Backer G, Reilly C, Elwyn G, Durand MA.

MDM Policy Pract. 2019 Nov 8;4(2):2381468319885871. doi: 10.1177/2381468319885871. eCollection 2019 Jul-Dec.

8.

The efficacy and safety of venetoclax therapy in elderly patients with relapsed, refractory chronic lymphocytic leukaemia.

Eyre TA, Roeker LE, Fox CP, Gohill SH, Walewska R, Walter HS, Forconi F, Broom A, Arumainathan A, Brander DM, Allan JN, Schuster SJ, Hill BT, Lansigan F, Cheson BD, Lamanna N, Coombs CC, Barr PM, Skarbnik AP, Shadman M, Ujjani CS, Pearson L, Pagel JM, Jacobs R, Mato AR.

Br J Haematol. 2019 Nov 4. doi: 10.1111/bjh.16271. [Epub ahead of print]

PMID:
31682002
9.

Sibling comparisons elucidate the associations between educational attainment polygenic scores and alcohol, nicotine and cannabis.

Salvatore JE, Barr PB, Stephenson M, Aliev F, Kuo SI, Su J, Agrawal A, Almasy L, Bierut L, Bucholz K, Chan G, Edenberg HJ, Johnson EC, McCutcheon VV, Meyers JL, Schuckit M, Tischfield J, Wetherill L, Dick DM.

Addiction. 2020 Feb;115(2):337-346. doi: 10.1111/add.14815. Epub 2019 Oct 28.

PMID:
31659820
10.

Five-year outcomes of the S1106 study of R-hyper-CVAD vs R-bendamustine in transplant-eligible patients with mantle cell lymphoma.

Kamdar M, Li H, Chen RW, Rimsza LM, Leblanc ML, Fenske TS, Shea TC, Barr PM, Phillips TJ, Leonard JP, Kahl BS, Friedberg JW, Smith SM.

Blood Adv. 2019 Oct 22;3(20):3132-3135. doi: 10.1182/bloodadvances.2019000526. No abstract available.

11.

FinnTwin12 Cohort: An Updated Review.

Rose RJ, Salvatore JE, Aaltonen S, Barr PB, Bogl LH, Byers HA, Heikkilä K, Korhonen T, Latvala A, Palviainen T, Ranjit A, Whipp AM, Pulkkinen L, Dick DM, Kaprio J.

Twin Res Hum Genet. 2019 Oct;22(5):302-311. doi: 10.1017/thg.2019.83. Epub 2019 Oct 23.

PMID:
31640839
12.

Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study.

Burger JA, Barr PM, Robak T, Owen C, Ghia P, Tedeschi A, Bairey O, Hillmen P, Coutre SE, Devereux S, Grosicki S, McCarthy H, Simpson D, Offner F, Moreno C, Dai S, Lal I, Dean JP, Kipps TJ.

Leukemia. 2019 Oct 18. doi: 10.1038/s41375-019-0602-x. [Epub ahead of print]

PMID:
31628428
13.

Significant weight gain in CLL patients treated with Ibrutinib: A potentially deleterious consequence of therapy.

Williams AM, Baran AM, Schaffer M, Bushart J, Rich L, Moore J, Barr PM, Zent CS.

Am J Hematol. 2020 Jan;95(1):E16-E18. doi: 10.1002/ajh.25663. Epub 2019 Nov 3. No abstract available.

PMID:
31621100
14.

A retrospective study on the acceptability, feasibility, and effectiveness of LoveYourBrain Yoga for people with traumatic brain injury and caregivers.

Donnelly KZ, Baker K, Pierce R, St Ivany AR, Barr PJ, Bruce ML.

Disabil Rehabil. 2019 Oct 2:1-12. doi: 10.1080/09638288.2019.1672109. [Epub ahead of print]

PMID:
31577456
15.

Nutrient Deficiency-Related Dermatoses after Bariatric Surgery.

Chu AS, Mataga MA, Krueger L, Barr PA.

Adv Skin Wound Care. 2019 Oct;32(10):443-455. doi: 10.1097/01.ASW.0000579688.97532.18.

PMID:
31567451
16.

Design and Development of the Brain Training System for the Digital "Maintain Your Brain" Dementia Prevention Trial.

Walton CC, Lampit A, Boulamatsis C, Hallock H, Barr P, Ginige JA, Brodaty H, Chau T, Heffernan M, Sachdev PS, Fiatarone Singh MA, Valenzuela M.

JMIR Aging. 2019 Feb 27;2(1):e13135. doi: 10.2196/13135.

17.

Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma.

Munir T, Brown JR, O'Brien S, Barrientos JC, Barr PM, Reddy NM, Coutre S, Tam CS, Mulligan SP, Jaeger U, Kipps TJ, Moreno C, Montillo M, Burger JA, Byrd JC, Hillmen P, Dai S, Szoke A, Dean JP, Woyach JA.

Am J Hematol. 2019 Dec;94(12):1353-1363. doi: 10.1002/ajh.25638. Epub 2019 Oct 13.

18.

Implementation of the uterine fibroids Option Grid patient decision aids across five organizational settings: a randomized stepped-wedge study protocol.

Scalia P, Durand MA, Forcino RC, Schubbe D, Barr PJ, O'Brien N, O'Malley AJ, Foster T, Politi MC, Laughlin-Tommaso S, Banks E, Madden T, Anchan RM, Aarts JWM, Velentgas P, Balls-Berry J, Bacon C, Adams-Foster M, Mulligan CC, Venable S, Cochran NE, Elwyn G.

Implement Sci. 2019 Sep 2;14(1):88. doi: 10.1186/s13012-019-0933-z.

19.

Evaluating Neighborhood, Social, and Genetic Influences on Precursors of Alcohol Use Risk Behavior in African American Adolescents.

Compton KS, Barr P, Karriker-Jaffe KJ, Bares C, Aliev F, Mustanski B, Dick D, Chartier KG.

Int J Environ Res Public Health. 2019 Aug 24;16(17). pii: E3078. doi: 10.3390/ijerph16173078.

20.

Chronic Condition Measurement Requires Engagement, Not Measurement Alone.

Austin AM, Carmichael D, Berry S, Gozansky WS, Nelson EC, Skinner JS, Barr PJ.

J Ambul Care Manage. 2019 Oct/Dec;42(4):295-304. doi: 10.1097/JAC.0000000000000300.

PMID:
31449165
21.

Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia.

Kipps TJ, Fraser G, Coutre SE, Brown JR, Barrientos JC, Barr PM, Byrd JC, O'Brien SM, Dilhuydy MS, Hillmen P, Jaeger U, Moreno C, Cramer P, Stilgenbauer S, Chanan-Khan AA, Mahler M, Salman M, Eckert K, Solman IG, Balasubramanian S, Cheng M, Londhe A, Ninomoto J, Howes A, James DF, Hallek M.

Clin Lymphoma Myeloma Leuk. 2019 Nov;19(11):715-722.e6. doi: 10.1016/j.clml.2019.07.004. Epub 2019 Jul 15.

22.

A cross-trial comparison of single-agent ibrutinib versus chlorambucil-obinutuzumab in previously untreated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.

Tedeschi A, Greil R, Demirkan F, Robak T, Moreno C, Barr PM, Anz B, Simpson D, Gaidano G, Bairey O, Stevens D, Gill D, Flinn IW, Kipps TJ, Burger JA, Lin J, Webb T, Fedorov V, Styles L, Gribben JG.

Haematologica. 2019 Aug 14. pii: haematol.2019.223743. doi: 10.3324/haematol.2019.223743. [Epub ahead of print]

23.

Nivolumab Combined With Brentuximab Vedotin for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Efficacy and Safety From the Phase II CheckMate 436 Study.

Zinzani PL, Santoro A, Gritti G, Brice P, Barr PM, Kuruvilla J, Cunningham D, Kline J, Johnson NA, Mehta-Shah N, Manley T, Francis S, Sharma M, Moskowitz AJ.

J Clin Oncol. 2019 Nov 20;37(33):3081-3089. doi: 10.1200/JCO.19.01492. Epub 2019 Aug 9.

PMID:
31398081
24.

Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia.

Shanafelt TD, Wang XV, Kay NE, Hanson CA, O'Brien S, Barrientos J, Jelinek DF, Braggio E, Leis JF, Zhang CC, Coutre SE, Barr PM, Cashen AF, Mato AR, Singh AK, Mullane MP, Little RF, Erba H, Stone RM, Litzow M, Tallman M.

N Engl J Med. 2019 Aug 1;381(5):432-443. doi: 10.1056/NEJMoa1817073.

25.

Heart sounds: a pilot randomised trial to determine the feasibility and acceptability of audio recordings to improve discharge communication for cardiology inpatients protocol.

Schott SL, Dannenberg MD, Dodge SE, Schoonmaker JA, Caisse MM, Barr PJ, O'Malley AJ, Bruce ML.

Open Heart. 2019 Jul 11;6(2):e001062. doi: 10.1136/openhrt-2019-001062. eCollection 2019. Erratum in: Open Heart. 2019 Oct 14;6(2):e001062corr1.

26.

Follicular Lymphoma: Recent and Emerging Therapies, Treatment Strategies, and Remaining Unmet Needs.

Matasar MJ, Luminari S, Barr PM, Barta SK, Danilov AV, Hill BT, Phillips TJ, Jerkeman M, Magagnoli M, Nastoupil LJ, Persky DO, Okosun J.

Oncologist. 2019 Nov;24(11):e1236-e1250. doi: 10.1634/theoncologist.2019-0138. Epub 2019 Jul 25. Review.

27.

Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III/IV Hodgkin lymphoma.

Stephens DM, Li H, Schöder H, Straus DJ, Moskowitz CH, LeBlanc M, Rimsza LM, Bartlett NL, Evens AM, LaCasce AS, Barr PM, Knopp MV, Hsi ED, Leonard JP, Kahl BS, Smith SM, Friedberg JW.

Blood. 2019 Oct 10;134(15):1238-1246. doi: 10.1182/blood.2019000719.

PMID:
31331918
28.

Patients with diffuse large B-cell lymphoma requiring urgent treatment: its implication on trial design and interpretation.

Loh KP, Baran A, Lee CY, Alshaibani A, Rutherford SC, Hu J, Casulo C, Barr PM, Friedberg JW, Reagan PM.

Leuk Lymphoma. 2019 Dec;60(14):3569-3572. doi: 10.1080/10428194.2019.1639172. Epub 2019 Jul 8. No abstract available.

PMID:
31282781
29.

Correction to: Genetics of Perceived Family Interaction From 12 to 17 Years of Age.

Silventoinen K, Su J, Pulkkinen L, Barr P, Rose RJ, Dick DM, Kaprio J.

Behav Genet. 2019 Sep;49(5):484. doi: 10.1007/s10519-019-09963-w.

30.

Too harts, won sole: Using dysgraphia treatment to address homophone representation.

Barr P, Biedermann B, Tainturier MJ, Kohnen S, Nickels L.

Neuropsychol Rehabil. 2019 Jul 1:1-32. doi: 10.1080/09602011.2019.1629302. [Epub ahead of print]

PMID:
31257990
31.

Polygenic risk for alcohol misuse is moderated by romantic partnerships.

Barr PB, Kuo SI, Aliev F, Latvala A, Viken R, Rose RJ, Kaprio J, Salvatore JE, Dick DM.

Addiction. 2019 Oct;114(10):1753-1762. doi: 10.1111/add.14712. Epub 2019 Jul 30.

PMID:
31240774
32.

Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.

Coutre SE, Byrd JC, Hillmen P, Barrientos JC, Barr PM, Devereux S, Robak T, Kipps TJ, Schuh A, Moreno C, Furman RR, Burger JA, O'Dwyer M, Ghia P, Valentino R, Chang S, Dean JP, James DF, O'Brien SM.

Blood Adv. 2019 Jun 25;3(12):1799-1807. doi: 10.1182/bloodadvances.2018028761.

33.

The association between Food and Alcohol Disturbance (FAD), race, and ethnic identity belonging.

Peralta RL, Schnellinger RP, Wade JM, Barr PB, Carter JR.

Eat Weight Disord. 2019 Aug;24(4):705-714. doi: 10.1007/s40519-019-00718-4. Epub 2019 Jun 4.

PMID:
31165446
34.

Genetics of Perceived Family Interaction From 12 to 17 Years of Age.

Silventoinen K, Su J, Pulkkinen L, Barr P, Rose RJ, Dick DM, Kaprio J.

Behav Genet. 2019 Jul;49(4):366-375. doi: 10.1007/s10519-019-09960-z. Epub 2019 May 24. Erratum in: Behav Genet. 2019 Jul 1;:.

35.

A retrospective comparison of venetoclax alone or in combination with an anti-CD20 monoclonal antibody in R/R CLL.

Mato AR, Roeker LE, Eyre TA, Nabhan C, Lamanna N, Hill BT, Brander DM, Barr PM, Lansigan F, Cheson BD, Singavi AK, Yazdy MS, Shah NN, Allan JN, Bhavsar EB, Rhodes J, Kennard K, Schuster SJ, Williams AM, Skarbnik AP, Goy AH, Goodfriend JM, Dorsey C, Coombs CC, Tuncer H, Ujjani CS, Jacobs R, Winter AM, Pagel JM, Bailey N, Schuh A, Shadman M, Sitlinger A, Weissbrot H, Muralikrishnan S, Zelenetz A, Kirkwood AA, Fox CP.

Blood Adv. 2019 May 28;3(10):1568-1573. doi: 10.1182/bloodadvances.2019000180.

36.

Multicentre retrospective study of intravascular large B-cell lymphoma treated at academic institutions within the United States.

Geer M, Roberts E, Shango M, Till BG, Smith SD, Abbas H, Hill BT, Kaplan J, Barr PM, Caimi P, Stephens DM, Lin E, Herrera AF, Rosenbaum E, Amengual JE, Boonstra PS, Devata S, Wilcox RA, Kaminski MS, Phillips TJ.

Br J Haematol. 2019 Jul;186(2):255-262. doi: 10.1111/bjh.15923. Epub 2019 May 1.

PMID:
31044423
37.

Genes, Roommates, and Residence Halls: A Multidimensional Study of the Role of Peer Drinking on College Students' Alcohol Use.

Smith RL, Salvatore JE, Aliev F, Neale Z, Barr P; Spit for Science Working Group, Dick DM.

Alcohol Clin Exp Res. 2019 Jun;43(6):1254-1262. doi: 10.1111/acer.14037. Epub 2019 Apr 29.

PMID:
31034622
38.

Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical Practice.

Roeker LE, Fox CP, Eyre TA, Brander DM, Allan JN, Schuster SJ, Nabhan C, Hill BT, Shah NN, Lansigan F, Yazdy M, Cheson BD, Lamanna N, Singavi AK, Coombs CC, Barr PM, Skarbnik AP, Shadman M, Ujjani CS, Tuncer HH, Winter AM, Rhodes J, Dorsey C, Morse H, Kabel C, Pagel JM, Williams AM, Jacobs R, Goy A, Muralikrishnan S, Pearson L, Sitlinger A, Bailey N, Schuh A, Kirkwood AA, Mato AR.

Clin Cancer Res. 2019 Jul 15;25(14):4264-4270. doi: 10.1158/1078-0432.CCR-19-0361. Epub 2019 Apr 19.

PMID:
31004001
39.

Healthcare Options for People Experiencing Depression (HOPE*D): the development and pilot testing of an encounter-based decision aid for use in primary care.

Barr PJ, Forcino RC, Dannenberg MD, Mishra M, Turner E, Zisman-Ilani Y, Matthews J, Hinn M, Bruce M, Elwyn G.

BMJ Open. 2019 Apr 8;9(4):e025375. doi: 10.1136/bmjopen-2018-025375.

40.

Utility of positron emission tomography-computed tomography in patients with chronic lymphocytic leukemia following B-cell receptor pathway inhibitor therapy.

Mato AR, Wierda WG, Davids MS, Cheson BD, Coutre SE, Choi M, Furman RR, Heffner L, Barr PM, Eradat H, Ford SM, Zhou L, Verdugo M, Humerickhouse RA, Potluri J, Byrd JC.

Haematologica. 2019 Nov;104(11):2258-2264. doi: 10.3324/haematol.2018.207068. Epub 2019 Mar 28.

41.

Augmenting Indolent Lymphoma Treatment Options With the Combination of Lenalidomide and Rituximab.

Barr PM.

J Clin Oncol. 2019 May 10;37(14):1151-1153. doi: 10.1200/JCO.19.00419. Epub 2019 Mar 22. No abstract available.

PMID:
30901301
42.

Developing community-based health education strategies with family history: Assessing the association between community resident family history and interest in health education.

Prom-Wormley EC, Clifford JS, Bourdon JL, Barr P, Blondino C, Ball KM, Montgomery J, Davis JK, Real JE, Edwards AC, Thiselton DL, Creighton GC, Wilson D, Newbille C.

Soc Sci Med. 2019 Feb 19:112160. doi: 10.1016/j.socscimed.2019.02.011. [Epub ahead of print]

PMID:
30862375
43.

Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab.

Byrd JC, Hillmen P, O'Brien S, Barrientos JC, Reddy NM, Coutre S, Tam CS, Mulligan SP, Jaeger U, Barr PM, Furman RR, Kipps TJ, Thornton P, Moreno C, Montillo M, Pagel JM, Burger JA, Woyach JA, Dai S, Vezan R, James DF, Brown JR.

Blood. 2019 May 9;133(19):2031-2042. doi: 10.1182/blood-2018-08-870238. Epub 2019 Mar 6.

PMID:
30842083
44.

Outcomes with ibrutinib by line of therapy and post-ibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysis.

O'Brien SM, Byrd JC, Hillmen P, Coutre S, Brown JR, Barr PM, Barrientos JC, Devereux S, Robak T, Reddy NM, Kipps TJ, Tedeschi A, Cymbalista F, Ghia P, Chang S, Ninomoto J, James DF, Burger JA.

Am J Hematol. 2019 May;94(5):554-562. doi: 10.1002/ajh.25436. Epub 2019 Mar 8.

45.

Tumour debulking and reduction in predicted risk of tumour lysis syndrome with single-agent ibrutinib in patients with chronic lymphocytic leukaemia.

Wierda WG, Byrd JC, O'Brien S, Coutre S, Barr PM, Furman RR, Kipps TJ, Burger JA, Stevens DA, Sharman J, Ghia P, Flinn IW, Zhou C, Ninomoto J, James DF, Tam CS.

Br J Haematol. 2019 Jul;186(1):184-188. doi: 10.1111/bjh.15791. Epub 2019 Feb 10. No abstract available.

PMID:
30740654
46.

Ibrutinib provides favourable survival outcomes in patients with comorbidities versus established therapies.

Burger JA, Cramer P, Barr PM, Dilhuydy MS, Mato A, Byrd JC, Chang S, Graef T, Lin T, Tedeschi A.

Br J Haematol. 2019 Jul;186(1):175-180. doi: 10.1111/bjh.15784. Epub 2019 Feb 10. No abstract available.

PMID:
30739324
47.

How I treat early-relapsing follicular lymphoma.

Casulo C, Barr PM.

Blood. 2019 Apr 4;133(14):1540-1547. doi: 10.1182/blood-2018-08-822148. Epub 2019 Jan 30. Review.

PMID:
30700421
48.

Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL.

Woyach JA, Ruppert AS, Heerema NA, Zhao W, Booth AM, Ding W, Bartlett NL, Brander DM, Barr PM, Rogers KA, Parikh SA, Coutre S, Hurria A, Brown JR, Lozanski G, Blachly JS, Ozer HG, Major-Elechi B, Fruth B, Nattam S, Larson RA, Erba H, Litzow M, Owen C, Kuzma C, Abramson JS, Little RF, Smith SE, Stone RM, Mandrekar SJ, Byrd JC.

N Engl J Med. 2018 Dec 27;379(26):2517-2528. doi: 10.1056/NEJMoa1812836. Epub 2018 Dec 1.

49.

End-user views of an electronic encounter decision aid linked to routine depression screening.

Dannenberg MD, Bienvenida JCM, Bruce ML, Nguyen T, Hinn M, Matthews J, Bartels SJ, Elwyn G, Barr PJ.

Patient Educ Couns. 2019 Mar;102(3):555-563. doi: 10.1016/j.pec.2018.10.002. Epub 2018 Oct 3.

PMID:
30497800
50.

Venetoclax for chronic lymphocytic leukaemia patients who progress after more than one B-cell receptor pathway inhibitor.

Wierda WG, Byrd JC, Davids MS, Furman RR, Cheson BD, Barr PM, Eradat H, Heffner L, Zhou L, Verdugo M, Potluri J, Choi M.

Br J Haematol. 2019 Jun;185(5):961-966. doi: 10.1111/bjh.15666. Epub 2018 Nov 27. No abstract available.

Supplemental Content

Support Center